Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Appili Therapeutics Inc. has reported a milestone achievement with the FDA approval and subsequent commercial launch of LIKMEZ™, a metronidazole oral suspension for treating anaerobic bacterial infections. The company has also secured significant funding from the U.S. Air Force Academy to advance its biodefense vaccine candidate, ATI-1701, towards an IND submission. Additionally, Appili is progressing with its antiparasitic product, ATI-1801, which is in advanced clinical development and may qualify for a priority review voucher.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
